Kenneth T. Mills Regenxbio Inc. (RGNX) insider trading activity

Kenneth T. Mills is President and CEO of REGENXBIO Inc.. Currently has a direct ownership of 408,035 shares of RGNX, which is worth approximately $4.45 Million. The most recent transaction as insider was on May 14, 2024, when has been sold 15,000 shares (Common Stock) at a price of $15.81 per share, resulting in proceeds of $237,150. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 408K

0% 3M change

35.77% 12M change

Total Value Held $4.45 Million

Kenneth T. Mills Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 14 2024	SELL Open market or private sale	$237,150 $15.81 p/Share	15,000 Reduced 3.55%	408,035 Common Stock
May 14 2024	BUY Exercise of conversion of derivative security	$56,400 $3.76 p/Share	15,000 Added 3.42%	423,035 Common Stock
Apr 15 2024	SELL Open market or private sale	$272,850 $18.19 p/Share	15,000 Reduced 3.55%	408,035 Common Stock
Apr 15 2024	BUY Exercise of conversion of derivative security	$56,400 $3.76 p/Share	15,000 Added 3.42%	423,035 Common Stock
Mar 14 2024	SELL Open market or private sale	$327,900 $21.86 p/Share	15,000 Reduced 3.55%	408,035 Common Stock
Mar 14 2024	BUY Exercise of conversion of derivative security	$56,400 $3.76 p/Share	15,000 Added 3.42%	423,035 Common Stock
Feb 14 2024	SELL Open market or private sale	$250,050 $16.67 p/Share	15,000 Reduced 3.55%	408,035 Common Stock

Feb 14 2024	BUY Exercise of conversion of derivative security	$56,400 $3.76 p/Share	15,000 Added 3.42%	423,035 Common Stock
Jan 16 2024	SELL Open market or private sale	$683,100 $15.18 p/Share	45,000 Reduced 9.93%	408,035 Common Stock
Jan 16 2024	BUY Exercise of conversion of derivative security	$169,200 $3.76 p/Share	45,000 Added 9.04%	453,035 Common Stock
Jan 02 2024	SELL Payment of exercise price or tax liability	$203,858 $17.95 p/Share	11,357 Reduced 3.2%	343,932 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	64,103 Added 13.58%	408,035 Common Stock
Dec 19 2023	SELL Open market or private sale	$885,600 $19.68 p/Share	45,000 Reduced 11.24%	355,289 Common Stock
Dec 19 2023	BUY Exercise of conversion of derivative security	$103,950 $2.31 p/Share	45,000 Added 10.11%	400,289 Common Stock
Jan 03 2023	SELL Payment of exercise price or tax liability	$211,105 $22.68 p/Share	9,308 Reduced 3.0%	300,536 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	54,753 Added 13.35%	355,289 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	35,796 Added 10.36%	309,844 Common Stock
Jan 01 2022	SELL Payment of exercise price or tax liability	$118,897 $32.7 p/Share	3,636 Reduced 1.31%	274,048 Common Stock
Dec 02 2021	SELL Bona fide gift	-	3,300 Reduced 1.17%	277,684 Common Stock
Nov 08 2021	SELL Open market or private sale	$60,000 $40.0 p/Share	1,500 Reduced 0.53%	280,984 Common Stock
Nov 08 2021	BUY Exercise of conversion of derivative security	$5,640 $3.76 p/Share	1,500 Added 0.53%	282,484 Common Stock
Sep 27 2021	SELL Open market or private sale	$63,285 $42.19 p/Share	1,500 Reduced 0.53%	280,984 Common Stock
Sep 27 2021	BUY Exercise of conversion of derivative security	$5,640 $3.76 p/Share	1,500 Added 0.53%	282,484 Common Stock
Sep 14 2021	SELL Open market or private sale	$1,578,850 $45.11 p/Share	35,000 Reduced 11.08%	280,984 Common Stock
Sep 14 2021	BUY Exercise of conversion of derivative security	$80,850 $2.31 p/Share	35,000 Added 9.97%	315,984 Common Stock

KTM

Kenneth T. Mills

President and CEO

Rockville, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RGNX shares.

Notify only if

Value

Insider Trading

Get notified when an Regenxbio Inc. insider buys or sells RGNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENXBIO Inc.

Track Activities on RGNX

Account